(Total Views: 354)
Posted On: 11/27/2019 10:58:00 AM
Post# of 72447
Two important takeaways from Mr. Ehrlich's letter. Note the use of the plural in the 2nd paragraph.
Quote:
The Brilacidin for the planned UC study is now in the hands of our manufacturing partner to be formulated for targeted delivery to the colon and documents have been submitted to health authorities for the study.....
Oral Mucositis
We are engaged in licensing discussions with potential business partners for Brilacidin for the prevention of severe oral mucositis. In addition, we retained a prominent advisory company to help us with plans for this asset...... If we don’t receive an appropriate licensing offer, we will seek an internal pathway to begin advanced late stage clinical trials.
Read More: https://investorshangout.com/post/view?id=560...z66UhE8DOE
(4)
(1)
